AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 292: E1775-E1781, 2007. First published February 13, 2007; doi:10.1152/ajpendo.00624.2006
0193-1849/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/6/E1775    most recent
00624.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cusi, K.
Right arrow Articles by Cersosimo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cusi, K.
Right arrow Articles by Cersosimo, E.

Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes

Kenneth Cusi,1,2 Sangeeta Kashyap,1 Amalia Gastaldelli,1 Mandeep Bajaj,1 and Eugenio Cersosimo1

1Diabetes Division, Department of Medicine; and 2Audie L. Murphy Veterans Administration Medical Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas

Submitted 17 November 2006 ; accepted in final form 6 February 2007

Elevated plasma FFA cause beta-cell lipotoxicity and impair insulin secretion in nondiabetic subjects predisposed to type 2 diabetes mellitus [T2DM; i.e., with a strong family history of T2DM (FH+)] but not in nondiabetic subjects without a family history of T2DM. To determine whether lowering plasma FFA with acipimox, an antilipolytic nicotinic acid derivative, may enhance insulin secretion, nine FH+ volunteers were admitted twice and received in random order either acipimox or placebo (double-blind) for 48 h. Plasma glucose/insulin/C-peptide concentrations were measured from 0800 to 2400. On day 3, insulin secretion rates (ISRs) were assessed during a +125 mg/dl hyperglycemic clamp. Acipimox reduced 48-h plasma FFA by 36% (P < 0.001) and increased the plasma C-peptide relative to the plasma glucose concentration or {Delta}C-peptide/{Delta}glucose AUC (+177%, P = 0.02), an index of improved beta-cell function. Acipimox improved insulin sensitivity (M/I) 26.1 ± 5% (P < 0.04). First- (+19 ± 6%, P = 0.1) and second-phase (+31 ± 6%, P = 0.05) ISRs during the hyperglycemic clamp also improved. This was particularly evident when examined relative to the prevailing insulin resistance [1/(M/I)], as both first- and second-phase ISR markedly increased by 29 ± 7 (P < 0.05) and 41 ± 8% (P = 0.02). There was an inverse correlation between fasting FFA and first-phase ISR (r2 = 0.31, P < 0.02) and acute (2–4 min) glucose-induced insulin release after acipimox (r2 =0.52, P < 0.04). In this proof-of-concept study in FH+ individuals predisposed to T2DM, a 48-h reduction of plasma FFA improves day-long meal and glucose-stimulated insulin secretion. These results provide additional evidence for the important role that plasma FFA play regarding insulin secretion in FH+ subjects predisposed to T2DM.

insulin resistance; lipotoxicity; beta-cell; family history of T2DM



Address for reprint requests and other correspondence: K. Cusi, The Univ. of Texas H. S. C. at San Antonio, Diabetes Division, Rm. 3.380S,7703 Floyd Curl Drive, San Antonio, TX 78284-3900 (e-mail: cusi{at}uthscsa.edu)




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Xiao, A. Giacca, and G. F. Lewis
The effect of high-dose sodium salicylate on chronically elevated plasma nonesterified fatty acid-induced insulin resistance and {beta}-cell dysfunction in overweight and obese nondiabetic men
Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1205 - E1211.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
P. Iozzo
Viewpoints on the Way to the Consensus Session: Where does insulin resistance start? The adipose tissue
Diabetes Care, November 1, 2009; 32(suppl_2): S168 - S173.
[Full Text] [PDF]


Home page
J. Physiol.Home page
C. Brøns, C. B. Jensen, H. Storgaard, N. J. Hiscock, A. White, J. S. Appel, S. Jacobsen, E. Nilsson, C. M. Larsen, A. Astrup, et al.
Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men
J. Physiol., May 15, 2009; 587(10): 2387 - 2397.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
American College of Endocrinology Pre-Diabetes Consensus Conference: Part Three
Diabetes Care, December 1, 2008; 31(12): 2404 - 2409.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.